基因组编辑诱导原发性β0 39-地中海贫血造血干/祖细胞治疗水平HbF
该研究采用CRISPR/Cas9结合NHEJ修复策略,在HBG启动子区模拟天然HPFH突变(-196 C>T),在HUDEP-2细胞及β0 39-地中海贫血患者HSPCs中评估HbF诱导效果。结果显示小缺失可恢复高水平HbF合成,患者HSPCs池中20%编辑带来约20% HbF平行增加,提示该策略对多数β-地中海贫血类型有治疗潜力。
要点
- 靶向HBG启动子-196区域的小缺失可恢复各测试细胞类型的高水平HbF合成。
- β0 39-地中海贫血患者HSPCs池中20%编辑导致HbF较未编辑池平行增加20%。
- 编辑HBG启动子-196附近区域可能对多数β-地中海贫血类型诱导治疗水平HbF。
核心结论
- 编辑HBG启动子-196附近区域有潜力在多数类型β-地中海贫血患者中诱导治疗水平HbF,不受HBB突变类型限制。
研究设计与样本
- 研究在K562细胞中筛选最有效guide RNA后,对HUDEP-2细胞及β0-地中海贫血患者来源HSPCs进行CRISPR/Cas9结合NHEJ的基因组编辑。
主要发现
- 靶向-196启动子区域的小缺失在所有测试细胞类型中恢复高水平HbF合成。
- 纯合β0 39-地中海贫血患者HSPCs池中,20%编辑导致HbF较未编辑池平行增加20%。
关键数值与推荐
- 纯合β0 39-地中海贫血患者HSPCs池中,20%编辑对应HbF较未编辑池增加20%。
临床怎么用
- 该策略可能适用于多数β-地中海贫血患者,不依赖于HBB突变类型。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Hereditary persistence of fetal haemoglobin (HPFH) is the major modifier of the clinical severity of β-thalassaemia. The homozygous mutation c.-196 C>T in the Aγ-globin (HBG1) promoter, which causes Sardinian δβ0 -thalassaemia, is able to completely rescue the β-major thalassaemia phenotype caused by the β0 39-thalassaemia mutation, ensuring high levels of fetal haemoglobin synthesis during adulthood. Here, we describe a CRISPR/Cas9 genome-editing approach, combined with the non-homologous end joining (NHEJ) pathway repair, aimed at reproducing the effects of this naturally occurring HPFH mutation in both HBG promoters. After selecting the most efficient guide RNA in K562 cells, we edited the HBG promoters in human umbilical cord blood-derived erythroid progenitor 2 cells (HUDEP-2) and in haematopoietic stem and progenitor cells (HSPCs) from β0 -thalassaemia patients to assess the therapeutic potential of HbF induction. Our results indicate that small deletions targeting the -196-promoter region restore high levels of fetal haemoglobin (HbF) synthesis in all cell types tested. In pools of HSPCs derived from homozygous β0 39-thalassaemia patients, a 20% editing determined a parallel 20% increase of HbF compared to unedited pools. These results suggest that editing the region of HBG promoters around the -196 position has the potential to induce therapeutic levels of HbF in patients with most types of β-thalassaemia irrespective of the β-globin gene (HBB) mutations.
引用
- Mingoia M, Caria CA, Ye L, et al. Induction of therapeutic levels of HbF in genome-edited primary β0 39-thalassaemia haematopoietic stem and progenitor cells. Br J Haematol. 2020. PMID: 33216968. doi:10.1111/bjh.17167
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。